<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841902</url>
  </required_header>
  <id_info>
    <org_study_id>REC/Lhr/21/1101 Danish Hassan</org_study_id>
    <nct_id>NCT04841902</nct_id>
  </id_info>
  <brief_title>Effects of Life Style Intervention Manual in Pre Hypertensive Sedentary Population</brief_title>
  <official_title>Effects of Life Style Intervention Manual on Metabolic, Cardiovascular, Respiratory and Physical Parameters in Pre Hypertensive Sedentary Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riphah International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riphah International University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypertension is an increasingly important medical and public health issue. The prevalence of&#xD;
      hypertension increases with advancing age to the point where more than half of people 60-69&#xD;
      years of age and approximately three-fourths of those 70 years of age and older are affected.&#xD;
      The age related rise in SBP is primarily responsible for an increase in both incidence and&#xD;
      prevalence of hypertension with increasing age. At present, it is estimated that about 1&#xD;
      billion people worldwide have hypertension (&gt;140/90 mmHg), and this number is expected to&#xD;
      increase to 1.56 billion by 2025.&#xD;
&#xD;
      Because of the new data on lifetime risk of hypertension and the impressive increase in the&#xD;
      risk of cardiovascular complications associated with levels of BP previously considered to be&#xD;
      normal, the JNC 7 report has introduced a new classification that includes the term&#xD;
      &quot;prehypertension&quot; for those with BPs ranging from 120-139 mmHg systolic and/or 80-89 mmHg&#xD;
      diastolic. This new designation is intended to identify those individuals in whom early&#xD;
      intervention by adoption of healthy lifestyles could reduce BP, decrease the rate of&#xD;
      progression of BP to hypertensive levels with age, or prevent hypertension entirely.&#xD;
      Prehypertension is not a disease category. Rather, it is a designation chosen to identify&#xD;
      individuals at high risk of developing hypertension, so that both patients and clinicians are&#xD;
      alerted to this risk and encouraged to intervene and prevent or delay the disease from&#xD;
      developing. Individuals who are pre hypertensive are not candidates for drug therapy based on&#xD;
      their level of BP and should be firmly and unambiguously advised to practice lifestyle&#xD;
      modification in order to reduce their risk of developing hypertension in the future.&#xD;
&#xD;
      The goal for individuals with prehypertension and no compelling indications is to lower BP to&#xD;
      normal levels with lifestyle changes, and prevent the progressive rise in BP using the&#xD;
      recommended lifestyle modifications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adoption of healthy lifestyles by all persons is critical for the prevention of high BP and&#xD;
      is an indispensable part of the management of those with hypertension. Weight loss of as&#xD;
      little as 10 lbs (4.5 kg) reduces BP and/or prevents hypertension in a large proportion of&#xD;
      overweight persons, although the ideal is to maintain normal body weight. BP is also&#xD;
      benefited by adoption of the Dietary approaches to Stop Hypertension (DASH) eating plan which&#xD;
      is a diet rich in fruits, vegetables, and low fat dairy products with a reduced content of&#xD;
      dietary cholesterol as well as saturated and total fat (modification of whole diet). It is&#xD;
      rich in potassium and calcium content. Dietary sodium should be reduced to no more than 100&#xD;
      mmol per day (2.4 g of sodium). Everyone who is able should engage in regular aerobic&#xD;
      physical activity such as brisk walking at least 30 minutes per day most days of the week.&#xD;
      Lifestyle modifications reduce BP, prevent or delay the incidence of hypertension, enhance&#xD;
      antihypertensive drug efficacy and decrease cardiovascular risk. For example, in some&#xD;
      individuals, a 1,600 mg sodium DASH eating plan has BP effects similar to single drug&#xD;
      therapy. Combinations of two (or more) lifestyle modifications can achieve even better&#xD;
      results. For overall cardiovascular risk reduction, patients should be strongly counseled to&#xD;
      quit smoking.&#xD;
&#xD;
      Lifestyle modification involves altering long-term habits, typically of eating or physical&#xD;
      activity, and maintaining the new behavior for months or years. Lifestyle changes are a more&#xD;
      natural way toward therapeutic goals and should be an integral component of halting or even&#xD;
      reversing early vascular aging as in pre hypertensive subjects. From a public health&#xD;
      perspective, even a small reduction in BP should have a tremendous, beneficial effect on the&#xD;
      occurrence of hypertension and its complications. In view of the current epidemic of&#xD;
      BP-related diseases and the proven effects of lifestyle modifications on BP, the current&#xD;
      challenge to health care providers, researchers, and public officials is to develop and&#xD;
      implement effective life style intervention program comprising exercise dietary and educative&#xD;
      component in clinical and public health strategies that achieve and maintain healthy&#xD;
      lifestyle modification&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Office, Ambulatory, Daytime, Nighttime &amp; 24 hours Systolic &amp; Diastolic Blood Pressure, Mean Arterial Blood Pressure measured at baseline, 8th Week post treatment and 16th Week post treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Triglycerides</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Serum Triglycerides measured at baseline, 8th Week post treatment and 16th Week post treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Body Mass Index (BMI) measured at baseline, 8th Week post treatment and 16th Week post treatment. BMI is calculated using height (m) and weight (kg) using the formula kg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Forced Vital Capacity (FVC) measured at baseline, 8th Week post treatment and 16th Week post treatment using a digital spirometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum Total Cholesterol</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Serum Total Cholesterol measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum High Density Lipoprotein (HDL-C)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Serum High Density Lipoprotein (HDL-C) measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Serum High Density Lipoprotein (LDL-C)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Serum High Density Lipoprotein (LDL-C) measured at baseline, 8th Week post treatment and 16th Week post treatment from intravenous blood specimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume - 01 Second (FEV1)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Forced Expiratory Volume - 01 Second (FEV1) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Forced Expiratory Volume 1 Second / Forced Vital Capacity (FEV1/FVC)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Forced Expiratory Volume 1 Second / Forced Vital Capacity (FEV1/FVC) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Peak Expiratory Flow Rate (PEFR)</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Peak Expiratory Flow Rate (PEFR) measured at baseline, 8th Week post treatment and 16th Week post treatment using digital spirometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Fat Percentage</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Body Fat Percentage measured at baseline, 8th Week post treatment and 16th Week post treatment using a body fat analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Waist-Hip Ratio</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Waist-Hip Ratio measured at baseline, 8th Week post treatment and 16th Week post treatment. Waist and hip circumference will be measured using inelastic tape.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hand Grip Strength</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Hand Grip Strength (Dominant &amp; Non Dominant)measured at baseline, 8th Week post treatment and 16th Week post treatment using Hand Held Dynamometer.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in VO2 Maximum</measure>
    <time_frame>16 Weeks</time_frame>
    <description>VO2 Maximum measured at baseline, 8th Week post treatment and 16th Week post treatment using treadmill.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Level of Perceived Exertion</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Level of Perceived Exertion measured at baseline, 8th Week post treatment and 16th Week post treatment using BROG scale.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pre Hypertension</condition>
  <arm_group>
    <arm_group_label>Life Style Intervention Manual (Supervised)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supervised Exercises with Life Style Intervention Manual (Dietary &amp; Educational Component) for 3 days / week for 16 weeks. Each session will comprise of 60 minutes of alternating light to moderate intensity aerobic exercises including warm up and rest interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Life Style Intervention Manual (Home Based)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home Based- Life Style Intervention Manual (Exercise, Dietary &amp; Educational Component for 16 weeks. Subject will be asked to maintain a regular exercise and dietary diary to ensure adherence to the program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Age matched Control Group followed for 16 weeks with General Advise to stay healthy and active</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Life Style Intervention Manual (With Exercise Under Supervision)</intervention_name>
    <description>Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. The exercise will be supervised will other two components will be home based.</description>
    <arm_group_label>Life Style Intervention Manual (Supervised)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>General Advice</intervention_name>
    <description>General advice to stay healthy and active</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Life Style Intervention Manual (Home Based)</intervention_name>
    <description>Life Style Intervention Manual for Pre Hypertensive subjects will consist of three components; Exercise, Dietary Modification and Education. All three components will be home based.</description>
    <arm_group_label>Life Style Intervention Manual (Home Based)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 25 - 40 years&#xD;
&#xD;
          2. Either gender&#xD;
&#xD;
          3. Clinic BP will be consistent with the diagnosis of pre-hypertension&#xD;
&#xD;
          4. Sedentary Subjects (&lt;150 min/week or &lt;600 MET-min/week on IPAQ Urdu Version)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index less than 18.5 kg/m2 or greater than 45 kg/m2&#xD;
&#xD;
          2. Evidence of target organ damage such as left ventricular hypertrophy, angina, heart&#xD;
             failure, stroke, chronic kidney disease, peripheral artery disease&#xD;
&#xD;
          3. Women of child-bearing age who tested positive for HCG &amp; breastfeeding women&#xD;
&#xD;
          4. Individuals who could not read the consent or Participated in another study within 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danish Hassan, PhD*</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riphah International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Syed Shakil ur Rehman, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Riphah International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Riphah Rehabiliation Clinic</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54770</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <reference>
    <citation>AlGhatrif M, Lakatta EG. The conundrum of arterial stiffness, elevated blood pressure, and aging. Curr Hypertens Rep. 2015 Feb;17(2):12. doi: 10.1007/s11906-014-0523-z. Review.</citation>
    <PMID>25687599</PMID>
  </reference>
  <reference>
    <citation>Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016 Aug 9;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.</citation>
    <PMID>27502908</PMID>
  </reference>
  <reference>
    <citation>Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015 Apr;38(4):227-36. doi: 10.1038/hr.2014.169. Epub 2014 Dec 11. Review.</citation>
    <PMID>25503845</PMID>
  </reference>
  <reference>
    <citation>Lee CJ, Kim JY, Shim E, Hong SH, Lee M, Jeon JY, Park S. The Effects of Diet Alone or in Combination with Exercise in Patients with Prehypertension and Hypertension: a Randomized Controlled Trial. Korean Circ J. 2018 Jul;48(7):637-651. doi: 10.4070/kcj.2017.0349.</citation>
    <PMID>29968437</PMID>
  </reference>
  <reference>
    <citation>Gerber M, Beck J, Brand S, Cody R, Donath L, Eckert A, Faude O, Fischer X, Hatzinger M, Holsboer-Trachsler E, Imboden C, Lang U, Mans S, Mikoteit T, Oswald A, PÃ¼hse U, Rey S, Schreiner AK, Schweinfurth N, Spitzer U, Zahner L. The impact of lifestyle Physical Activity Counselling in IN-PATients with major depressive disorders on physical activity, cardiorespiratory fitness, depression, and cardiovascular health risk markers: study protocol for a randomized controlled trial. Trials. 2019 Jun 20;20(1):367. doi: 10.1186/s13063-019-3468-3.</citation>
    <PMID>31221205</PMID>
  </reference>
  <reference>
    <citation>Zheng S, Lubin B, Au R, Murabito JM, Benjamin EJ, Shwartz M. Advantages of Continuous-Valued Risk Scores for Predicting Long-Term Costs: The Framingham Coronary Heart Disease 10-Year Risk Score. Adv Geriatr Med Res. 2019;1(1). pii: e190004. doi: 10.20900/agmr20190004. Epub 2019 Jun 6.</citation>
    <PMID>31448373</PMID>
  </reference>
  <reference>
    <citation>Zhang C, Zhang Y, Lin H, Liu S, Xie J, Tang Y, Huang H, Zhang W. Blood pressure control in hypertensive patients and its relation with exercise and exercise-related behaviors: A case-control study. Medicine (Baltimore). 2020 Feb;99(8):e19269. doi: 10.1097/MD.0000000000019269.</citation>
    <PMID>32080136</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre Hypertension</keyword>
  <keyword>Lifestyle Intervention</keyword>
  <keyword>Metabolic parameters</keyword>
  <keyword>Cardiovascular parameters</keyword>
  <keyword>Respiratory parameters</keyword>
  <keyword>Physical parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

